AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25714759 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary elimination of isofurans in the first 4 days after birth
Number of subjects: 254
Study 22552590 — intervention group
Group type: EXPERIMENTAL
Intervention: Safflower oil
Number of subjects: 8
Study 22552590 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 8
Study 22552590 — intervention group
Group type: EXPERIMENTAL
Intervention: Linseed oil
Number of subjects: 8
Study 22552590 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine (positive control)
Number of subjects: 8
Study 22552590 — intervention group
Group type: COMPARATOR
Intervention: Non-rinsed control samples (negative control)
Number of subjects: 8
Study 22561365 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenovirus serotype 5 (Ad5)‐vectored HIV vaccine
Number of subjects: 1836
Study 22561365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1836
Study 21203519 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo pills (inert substance, like sugar pills)
Number of subjects: 80
Study 21203519 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo pills
Number of subjects: 80
Study 21203519 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 80
Study 17425744 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (lower-C(2) range)
Number of subjects: 141
Study 17425744 — intervention group
Group type: COMPARATOR
Intervention: Group A (higher-C(2) range)
Number of subjects: 141
Study 17425744 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk patients
Number of subjects: 141
Study 17425744 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 141
Study 16320346 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/day) plus elemental calcium (1,200 mg/day)
Number of subjects: 33
Study 16320346 — intervention group
Group type: COMPARATOR
Intervention: Elemental calcium alone (control)
Number of subjects: 33
Study 12856761 — intervention group
Group type: EXPERIMENTAL
Intervention: Object of My Affection (treatment group)
Number of subjects: 0
Study 12856761 — intervention group
Group type: COMPARATOR
Intervention: Father of the Bride II (control group)
Number of subjects: 0
Study 9690406 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (n=398)
Number of subjects: 595
Study 9690406 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin (n=197)
Number of subjects: 595
Study 9690406 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (n=398) - Non-severe pneumonia
Number of subjects: 595
Study 9690406 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin (n=197) - Non-severe pneumonia
Number of subjects: 595
Study 9690406 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (n=398) - Severe pneumonia
Number of subjects: 595
Study 9690406 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin (n=197) - Severe pneumonia
Number of subjects: 595
Study 7989461 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (150 mg/day)
Number of subjects: 48
Study 7989461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 3053570 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiramycin 2 g orally daily
Number of subjects: 198
Study 3053570 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin 2 g orally daily
Number of subjects: 198
Study 29027771 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous popliteal sciatic nerve block at the bifurcation
Number of subjects: 40
Study 29027771 — intervention group
Group type: COMPARATOR
Intervention: Continuous popliteal sciatic nerve block proximal to the bifurcation
Number of subjects: 40
Study 27622692 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg (two injections at baseline and after 6 months, n=10)
Number of subjects: 24
Study 27622692 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg (n=10)
Number of subjects: 24
Study 27622692 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n=14)
Number of subjects: 24
Study 25603897 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-flow restricted resistance training (BFR)
Number of subjects: 10
Study 25603897 — intervention group
Group type: COMPARATOR
Intervention: Low-load traditional resistance training (low-load TRT)
Number of subjects: 10
Study 23899063 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with doxorubicin and paclitaxel
Number of subjects: 62
Study 23899063 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual Disease in Breast and Nodes (RDBN) classification
Number of subjects: 62
Study 23899063 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph node metastases
Number of subjects: 62
Study 23899063 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual Cancer Burden (RCB) scores
Number of subjects: 62
Study 23899063 — intervention group
Group type: EXPERIMENTAL
Intervention: Miller‐Payne grading and Sataloff tumor scores
Number of subjects: 62
Study 20070351 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once daily (N = 528)
Number of subjects: 1050
Study 20070351 — intervention group
Group type: COMPARATOR
Intervention: Metformin 1000 mg twice daily (N = 522)
Number of subjects: 1050
Study 20070351 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 1050
Study 20070351 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 1050
Study 18760583 — intervention group
Group type: EXPERIMENTAL
Intervention: TIO 18 microg once-daily (8 am) + FOR 12 microg (8 pm)
Number of subjects: 80
Study 18760583 — intervention group
Group type: EXPERIMENTAL
Intervention: FOR 12 microg twice-daily (8 am and 8 pm) + TIO 18 microg (8 pm)
Number of subjects: 80
Study 18760583 — intervention group
Group type: COMPARATOR
Intervention: Single-drug treatments
Number of subjects: 80
Study 18760583 — intervention group
Group type: EXPERIMENTAL
Intervention: Tr4 (TIO 18 microg (8 am) + FOR 12 microg twice-daily (8 am and 8 pm))
Number of subjects: 80
Study 18760583 — intervention group
Group type: EXPERIMENTAL
Intervention: Tr5 (FOR 12 microg twice-daily (8 am and 8 pm) + TIO 18 microg (8 pm))
Number of subjects: 80
Study 16826474 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP) treatment
Number of subjects: 1503
Study 12673696 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy regimens incorporating gemcitabine and paclitaxel with a platinum complex, with or without ifosfamide or doxorubicin
Number of subjects: 0
Study 12673696 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate/vinblastine/doxorubicin/cisplatin regimen
Number of subjects: 0
Study 12673696 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimens predicated on taxanes and gemcitabine
Number of subjects: 0
Study 12673696 — intervention group
Group type: COMPARATOR
Intervention: Standard single agents (methotrexate, doxorubicin, mitomycin, ifosfamide, vinblastine, cisplatin)
Number of subjects: 0
Study 12673696 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 0
Study 10502712 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 56
Study 10502712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 8895622 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsular closure with the knee in full extension
Number of subjects: 64
Study 8895622 — intervention group
Group type: COMPARATOR
Intervention: Capsular closure with the knee in flexion
Number of subjects: 64
Study 2049421 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial 24 hours lavage before resumption of routine CAPD schedule
Number of subjects: 36
Study 2049421 — intervention group
Group type: COMPARATOR
Intervention: Continued prolonged exchanges as in routine CAPD schedule
Number of subjects: 36
Study 6364688 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. injection of 15‐methyl PGF2 alpha, 0.25 mg every second hour
Number of subjects: 120
Study 6364688 — intervention group
Group type: EXPERIMENTAL
Intervention: 16‐phenoxy‐omega‐17,18,19,20‐tetranor PGE2 methyl sulfonyl‐amide, 0.5 mg every fourth hour
Number of subjects: 120
Study 6364688 — intervention group
Group type: EXPERIMENTAL
Intervention: laminaria tent
Number of subjects: 120
Study 6364688 — intervention group
Group type: COMPARATOR
Intervention: 15‐methyl PGF2 alpha
Number of subjects: 120
Study 6364688 — intervention group
Group type: COMPARATOR
Intervention: 16‐phenoxy‐omega‐17,18,19,20‐tetranor PGE2 methyl sulfonyl‐amide
Number of subjects: 120
Study 30312394 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap-on-a-rope intervention in intervention schools
Number of subjects: 50
Study 30312394 — intervention group
Group type: COMPARATOR
Intervention: Control schools (no intervention)
Number of subjects: 50
Study 29378502 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial anthropometric measurements using Digimizer version 4.1.1.0
Number of subjects: 50
Study 27191923 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (target concentration: young 3 ng/ml; old 2 ng/ml)
Number of subjects: 18
Study 27191923 — intervention group
Group type: COMPARATOR
Intervention: Morphine (dose: young 0.1 mg/kg; old 0.07 mg/kg)
Number of subjects: 18
Study 24183899 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle proprioceptive threshold (APrT)
Number of subjects: 42
Study 24183899 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip abduction rate of torque generation (RTG)
Number of subjects: 42
Study 24183899 — intervention group
Group type: COMPARATOR
Intervention: Injured subjects
Number of subjects: 42
Study 22200383 — intervention group
Group type: EXPERIMENTAL
Intervention: Active US therapy (20% duty cycle, 1MHz, average temporal intensity: 0.2W/cm(2), therapeutic dose: 112.5J/cm(2))
Number of subjects: 27
Study 22200383 — intervention group
Group type: COMPARATOR
Intervention: Sham US therapy (no sound-head crystal)
Number of subjects: 27
Study 21047602 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 × 1 ml Orthovisc(®) hyaluronic acid injections
Number of subjects: 26
Study 21047602 — intervention group
Group type: COMPARATOR
Intervention: 1 ml single dose Orthovisc(®) hyaluronic acid injections
Number of subjects: 26
Study 21047602 — intervention group
Group type: COMPARATOR
Intervention: 2 ml single dose Orthovisc(®) hyaluronic acid injections
Number of subjects: 26
Study 21047602 — intervention group
Group type: COMPARATOR
Intervention: 3 ml single dose Orthovisc(®) hyaluronic acid injections
Number of subjects: 26
Study 17685257 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with irinotecan + 5-FU + leucovorin
Number of subjects: 204
Study 17685257 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone (control group)
Number of subjects: 204
Study 14970837 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed-nutrient (MN) beverage
Number of subjects: 20
Study 14970837 — intervention group
Group type: COMPARATOR
Intervention: Sugar-only (SO) beverage
Number of subjects: 20
Study 11856774 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNSORB Pk treatment (n = 19)
Number of subjects: 31
Study 11856774 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (n = 12)
Number of subjects: 31
Study 11856774 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis required (acute phase)
Number of subjects: 31
Study 11856774 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute phase vs. convalescence
Number of subjects: 31
Study 11856774 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall bFGF levels
Number of subjects: 31
Study 9420337 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine
Number of subjects: 443
Study 9420337 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine followed by prednisone
Number of subjects: 443
Study 9420337 — intervention group
Group type: COMPARATOR
Intervention: Methimazole
Number of subjects: 443
Study 7702016 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusions of pure fat or carbohydrate (2092 kJ)
Number of subjects: 12
Study 7702016 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric infusions of fat or carbohydrate (2092 kJ)
Number of subjects: 12
Study 7702016 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow intragastric infusions of fat
Number of subjects: 12
Study 7702016 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow intragastric infusions of carbohydrate
Number of subjects: 12
Study 7702016 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally derived energy (2092-kJ yogurt preloads)
Number of subjects: 12
Study 7702016 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 12
Study 2614659 — intervention group
Group type: EXPERIMENTAL
Intervention: ATT-INT (counseling designed to alter attributions for unwanted pregnancy)
Number of subjects: 283
Study 2614659 — intervention group
Group type: EXPERIMENTAL
Intervention: EXP-INT (counseling designed to raise coping expectations)
Number of subjects: 283
Study 2614659 — intervention group
Group type: COMPARATOR
Intervention: Control (standard counseling)
Number of subjects: 283
Study 605738 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic drainage via Intracath device
Number of subjects: 55
Study 605738 — intervention group
Group type: COMPARATOR
Intervention: Urethral drainage via Foley Catheter
Number of subjects: 55
Study 605738 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic drainage
Number of subjects: 55
Study 605738 — intervention group
Group type: COMPARATOR
Intervention: Urethral drainage
Number of subjects: 55
Study 30079951 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (200 mg of ferrous fumarate weekly for 3 months)
Number of subjects: 131
Study 30079951 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation with nutrition education
Number of subjects: 131
Study 30079951 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 131
Study 26151734 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesamin 200 mg/day
Number of subjects: 44
Study 26151734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 25805668 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent vouchers (CV) for smoking abstinence
Number of subjects: 184
Study 25805668 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent vouchers (NCV)
Number of subjects: 184
Study 25805668 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent vouchers (CV) combined with motivational interviewing (MI)
Number of subjects: 184
Study 25805668 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent vouchers (CV) combined with brief advice (BA)
Number of subjects: 184
Study 23640622 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dialysate sodium concentration
Number of subjects: 40
Study 23640622 — intervention group
Group type: COMPARATOR
Intervention: Standard dialysate sodium concentration (138 mmol/L)
Number of subjects: 40
Study 20884297 — intervention group
Group type: EXPERIMENTAL
Intervention: HBVaxPro monovalent hepatitis B vaccine
Number of subjects: 1543
Study 20884297 — intervention group
Group type: EXPERIMENTAL
Intervention: Engerix B monovalent hepatitis B vaccine
Number of subjects: 1543
Study 20884297 — intervention group
Group type: COMPARATOR
Intervention: Hexavac
Number of subjects: 1543
Study 20884297 — intervention group
Group type: COMPARATOR
Intervention: Infanrix hexa
Number of subjects: 1543
Study 18209262 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling and educational map
Number of subjects: 237
Study 18209262 — intervention group
Group type: COMPARATOR
Intervention: Counseling only (Control group #1)
Number of subjects: 237
Study 18209262 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control group #2)
Number of subjects: 237
Study 15087038 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + Reduced Glutathione (GSH)
Number of subjects: 62
Study 15087038 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 62
Study 12032111 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg three times a day)
Number of subjects: 0
Study 12032111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12032111 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 0
Study 9810446 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-0127 (3.0 micrograms/kg/min)
Number of subjects: 20
Study 9810446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9810446 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-0127
Number of subjects: 20
Study 7759671 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye movement desensitization and reprocessing
Number of subjects: 5
Study 7759671 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroencephalographic (EEG) biofeedback
Number of subjects: 5
Study 7759671 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep pressure/touch therapies
Number of subjects: 5
Study 7759671 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress‐challenge treatments
Number of subjects: 5
Study 7759671 — intervention group
Group type: EXPERIMENTAL
Intervention: Confrontational scare treatments
Number of subjects: 5
Study 2496000 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil (35 mu b.i.d)
Number of subjects: 80
Study 2496000 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (400 mg b.i.d)
Number of subjects: 80
Study 769560 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminocaproic acid
Number of subjects: 59
Study 769560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 31432562 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 300
Study 31432562 — intervention group
Group type: COMPARATOR
Intervention: Vaginal progesterone
Number of subjects: 300
Study 31173130 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model (HeadXNet) augmentation
Number of subjects: 818
Study 31173130 — intervention group
Group type: COMPARATOR
Intervention: No augmentation
Number of subjects: 818
Study 28815552 — intervention group
Group type: EXPERIMENTAL
Intervention: Connect-Home intervention
Number of subjects: 145
Study 28815552 — intervention group
Group type: COMPARATOR
Intervention: Usual discharge planning (comparison dyads)
Number of subjects: 145
Study 26666596 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise treatment for 3-6 months to reduce body weight by >5%
Number of subjects: 60
Study 26666596 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study 23682110 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan (10 mg once daily)
Number of subjects: 178
Study 23682110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 23682110 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan
Number of subjects: 178
Study 21802649 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 g/kg (high dose)
Number of subjects: 0
Study 21802649 — intervention group
Group type: COMPARATOR
Intervention: 0.4 g/kg (low dose)
Number of subjects: 0
Study 21802649 — intervention group
Group type: COMPARATOR
Intervention: 0 g/kg (placebo)
Number of subjects: 0
Study 21802649 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (all doses)
Number of subjects: 0
Study 19046833 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive intervention targeting disruptive behavior problems
Number of subjects: 477
Study 19046833 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 477
Study 16960474 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal triamcinolone acetonide (6 injections every third day)
Number of subjects: 0
Study 16960474 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (MIX)
Number of subjects: 0
Study 15645893 — intervention group
Group type: EXPERIMENTAL
Intervention: 14% hydrogen-peroxide whitening strips
Number of subjects: 31
Study 15645893 — intervention group
Group type: COMPARATOR
Intervention: 9.5% hydrogen-peroxide custom-tray-based system
Number of subjects: 31
Study 11726088 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (1 mg)
Number of subjects: 29
Study 11726088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 9161943 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg oral vitamin K1 supplementation per week for 4 weeks
Number of subjects: 18
Study 9161943 — intervention group
Group type: COMPARATOR
Intervention: No supplementation for 4 weeks
Number of subjects: 18
Study 7910126 — intervention group
Group type: EXPERIMENTAL
Intervention: Khat (0.8 mg/kg body weight)
Number of subjects: 6
Study 7910126 — intervention group
Group type: COMPARATOR
Intervention: Alkaloid-free khat (placebo)
Number of subjects: 6
Study 3115546 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking intervention
Number of subjects: 255
Study 3115546 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 255
Study 31813317 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconference administration of MoCA
Number of subjects: 48
Study 31813317 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face administration of MoCA
Number of subjects: 48
Study 31916418 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizartinib after overnight fasting (n = 34)
Number of subjects: 64
Study 31916418 — intervention group
Group type: COMPARATOR
Intervention: Quizartinib after a high-fat, high-calorie meal (n = 30)
Number of subjects: 64
Study 29871369 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper one-third joint technique (group U)
Number of subjects: 181
Study 29871369 — intervention group
Group type: COMPARATOR
Intervention: Lower one-third joint technique (group L)
Number of subjects: 181
Study 27271500 — intervention group
Group type: EXPERIMENTAL
Intervention: SpeechEasy® device used daily for 6 months
Number of subjects: 18
Study 27271500 — intervention group
Group type: COMPARATOR
Intervention: 12-week fluency promotion protocol with techniques based on fluency shaping and stuttering modification
Number of subjects: 18
Study 22487170 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily physical education (5 × 45 min/week) and adapted motor training if needed
Number of subjects: 220
Study 22487170 — intervention group
Group type: COMPARATOR
Intervention: Control group (PE two lessons/week)
Number of subjects: 220